Literature DB >> 2261345

Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia.

D G Oscier1, J Stevens, T J Hamblin, R M Pickering, R Lambert, M Fitchett.   

Abstract

141 patients with B-cell chronic lymphocytic leukaemia (B-CLL) have been studied for a minimum of 12 months and a maximum of 25 years. 30 of 133 patients (32.5%) had greater than 10% FMC7 positive peripheral blood lymphocytes and 19 of 131 patients (14.5%) had a serum or urinary paraprotein. At presentation 88 patients were stage A0, 18 A1, 18 A2, 11 B and six C. 44 (31%) had progressive disease and 42 (30%) died during the study period. 63 patients had a normal karyotype, 75 a clonal abnormality and in three no metaphases were obtained. The finding of a complex karyotypic abnormality was significantly associated with lambda surface phenotype (P less than 0.01), the presence of greater than 10% FMC7 positive cells (P less than 0.025), and the presence of a paraprotein (P = 0.025). Patients whose leukaemic cells had a complex karyotype and those with structural abnormalities of chromosomes 14 and 6 required treatment earlier than those with a normal karyotype.

Entities:  

Mesh:

Year:  1990        PMID: 2261345     DOI: 10.1111/j.1365-2141.1990.tb06367.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  Karyotypic and molecular abnormalities in chronic lymphocytic leukaemia.

Authors:  C D Fegan; F E Davies
Journal:  Clin Mol Pathol       Date:  1996-08

2.  IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.

Authors:  D Rizzo; J Chauzeix; F Trimoreau; J B Woillard; F Genevieve; A Bouvier; J Labrousse; C Poli; E Guerin; N Dmytruk; L Remenieras; J Feuillard; N Gachard
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528

Review 3.  What is the best frontline therapy for patients with CLL and 17p deletion?

Authors:  Xavier C Badoux; Michael J Keating; William G Wierda
Journal:  Curr Hematol Malig Rep       Date:  2011-03       Impact factor: 3.952

4.  Is Cd11c and Fmc7 Negativity in Chronic Lymphocytic Leukemia Poor Prognostic?

Authors:  Aysun Şentürk Yikilmaz; Sema Akinci; Şule Mine Bakanay; Zeynep Büşra Zengin; İmdat Dilek
Journal:  Indian J Hematol Blood Transfus       Date:  2019-08-13       Impact factor: 0.900

Review 5.  Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia.

Authors:  Nitin Jain; Nicole Lamanna
Journal:  Curr Oncol Rep       Date:  2009-09       Impact factor: 5.075

6.  FISH Analysis for del6q21 and del17p13 in B-cell Chronic Lymphocytic Leukemia in Iranians.

Authors:  Hossein Teimori; Saeede Ashoori; Mohamad Taghi Akbari; Marjan Mojtabavi Naeini; Morteza Hashemzade Chaleshtori
Journal:  Iran Red Crescent Med J       Date:  2013-02-05       Impact factor: 0.611

7.  Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.

Authors:  Nina Kreuzberger; Johanna Aag Damen; Marialena Trivella; Lise J Estcourt; Angela Aldin; Lisa Umlauff; Maria Dla Vazquez-Montes; Robert Wolff; Karel Gm Moons; Ina Monsef; Farid Foroutan; Karl-Anton Kreuzer; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-07-31

Review 8.  Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go.

Authors:  Anna Puiggros; Gonzalo Blanco; Blanca Espinet
Journal:  Biomed Res Int       Date:  2014-05-22       Impact factor: 3.411

Review 9.  Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia.

Authors:  Maurizio Cavallari; Francesco Cavazzini; Antonio Cuneo; Gian Matteo Rigolin; Antonella Bardi; Eleonora Volta; Aurora Melandri; Elisa Tammiso; Elena Saccenti; Enrico Lista; Francesca Maria Quaglia; Antonio Urso; Michele Laudisi; Elisa Menotti; Luca Formigaro; Melissa Dabusti; Maria Ciccone; Paolo Tomasi; Massimo Negrini
Journal:  Oncotarget       Date:  2018-09-28

Review 10.  Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features.

Authors:  Lina van der Straten; Paul J Hengeveld; Arnon P Kater; Anton W Langerak; Mark-David Levin
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.